O'Shaughnessy JA - Search Results

1

Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data.

Fernandes LE, Epstein CG, Bobe AM, Bell JSK, Stumpe MC, Salazar ME, Salahudeen AA, Pe Benito RA, McCarter C, Leibowitz BD, Kase M, Igartua C, Huether R, Hafez A, Beaubier N, Axelson MD, Pegram MD, Sammons SL, O'Shaughnessy JA, Palmer GA. Fernandes LE, et al. Clin Breast Cancer. 2021 Aug;21(4):e340-e361. doi: 10.1016/j.clbc.2020.11.012. Epub 2020 Dec 18. Clin Breast Cancer. 2021. PMID: 33446413

2

Alpha-difluoromethylornithine as treatment for metastatic breast cancer patients.

O'Shaughnessy JA, Demers LM, Jones SE, Arseneau J, Khandelwal P, George T, Gersh R, Mauger D, Manni A. O'Shaughnessy JA, et al. Clin Cancer Res. 1999 Nov;5(11):3438-44. Clin Cancer Res. 1999. PMID: 10589756 Clinical Trial.

3

Pegylated liposomal doxorubicin in the treatment of breast cancer.

O'Shaughnessy JA. O'Shaughnessy JA. Clin Breast Cancer. 2003 Dec;4(5):318-28. doi: 10.3816/cbc.2003.n.037. Clin Breast Cancer. 2003. PMID: 14715106 Review.

4

Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer.

O'Shaughnessy JA, Vukelja S, Marsland T, Kimmel G, Ratnam S, Pippen JE. O'Shaughnessy JA, et al. Clin Breast Cancer. 2004 Jun;5(2):142-7. doi: 10.3816/cbc.2004.n.019. Clin Breast Cancer. 2004. PMID: 15245619 Clinical Trial.

5

Capecitabine/Taxane combination therapy: evolving clinical utility in breast cancer.

O'Shaughnessy JA, Blum JL. O'Shaughnessy JA, et al. Clin Breast Cancer. 2006 Apr;7(1):42-50. doi: 10.3816/CBC.2006.n.012. Clin Breast Cancer. 2006. PMID: 16764743 Review.

6

Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer.

Ewer MS, O'Shaughnessy JA. Ewer MS, et al. Clin Breast Cancer. 2007 Jun;7(8):600-7. Clin Breast Cancer. 2007. PMID: 17592672 Review.

7

Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer.

Loesch D, Asmar L, McIntyre K, Doane L, Monticelli M, Paul D, Vukelja S, Orlando M, Vaughn LG, Zhan F, Boehm KA, O'Shaughnessy JA. Loesch D, et al. Clin Breast Cancer. 2008 Apr;8(2):178-86. doi: 10.3816/CBC.2008.n.019. Clin Breast Cancer. 2008. PMID: 18621615 Clinical Trial.

8

Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer.

Smith JW 2nd, McIntyre KJ, Acevedo PV, Encarnacion CA, Tedesco KL, Wang Y, Asmar L, O'Shaughnessy JA. Smith JW 2nd, et al. Breast Cancer Res Treat. 2009 Nov;118(2):361-7. doi: 10.1007/s10549-009-0410-5. Epub 2009 May 21. Breast Cancer Res Treat. 2009. PMID: 19459042 Clinical Trial.

9

A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy.

Pippen J, Elias AD, Neubauer M, Stokoe C, Vaughn LG, Wang Y, Orlando M, Shonukan O, Muscato J, O'Shaughnessy JA, Gralow J. Pippen J, et al. Clin Breast Cancer. 2010 Apr;10(2):148-53. doi: 10.3816/CBC.2010.n.020. Clin Breast Cancer. 2010. PMID: 20299319 Clinical Trial.

10

Lethal breast cancer.

O'Shaughnessy JA. O'Shaughnessy JA. Clin Breast Cancer. 2010;10 Suppl 1:E6-7. doi: 10.3816/CBC.2010.s.001. Clin Breast Cancer. 2010. PMID: 20587408 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

193 results

Search Page